Autolus Therapeutics plc financial data

Symbol
AUTL on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
The Mediaworks, 191 Wood Lane, London, United Kingdom
State of incorporation
United Kingdom
Fiscal year end
December 31
Former names
Autolus Therapeutics Ltd (to 6/8/2018)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.28K % +53.5%
Debt-to-equity 80.9 % +9.16%
Return On Equity -66.8 % -2.9%
Return On Assets -36.9 % +0.97%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 266M shares
Entity Public Float 279M USD
Weighted Average Number of Shares Outstanding, Basic 266M shares +53%
Weighted Average Number of Shares Outstanding, Diluted 266M shares +53%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 137M USD +15.4%
General and Administrative Expense 66.4M USD +84.2%
Operating Income (Loss) -194M USD -27.8%
Nonoperating Income (Expense) -40.1M USD -1230%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -234M USD -51.2%
Income Tax Expense (Benefit) -2.5K USD -101%
Net Income (Loss) Attributable to Parent -234M USD -50.9%
Earnings Per Share, Basic -1.17 USD/shares +1.68%
Earnings Per Share, Diluted -1.17 USD/shares +1.68%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 706M USD +130%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD
Other Assets, Current 0 USD -100%
Assets, Current 759M USD +113%
Deferred Income Tax Assets, Net 3.22M USD +36.5%
Property, Plant and Equipment, Net 32.9M USD -10.8%
Operating Lease, Right-of-Use Asset 57.7M USD +6.32%
Assets 854M USD +89.3%
Accounts Payable, Current 1.1M USD -71.7%
Employee-related Liabilities, Current 10.5M USD
Accrued Liabilities, Current 35.6M USD +14.9%
Liabilities, Current 40.9M USD -0.39%
Contract with Customer, Liability, Noncurrent 239M USD +75.8%
Operating Lease, Liability, Noncurrent 45.8M USD +2.43%
Other Liabilities, Noncurrent 415K USD +240%
Liabilities 326M USD +47%
Accumulated Other Comprehensive Income (Loss), Net of Tax -27.9M USD +0.18%
Retained Earnings (Accumulated Deficit) -990M USD -31%
Stockholders' Equity Attributable to Parent 528M USD +130%
Liabilities and Equity 854M USD +89.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -40.5M USD +4.49%
Net Cash Provided by (Used in) Financing Activities 561M USD
Net Cash Provided by (Used in) Investing Activities -533K USD +85.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 519M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 707M USD +130%
Deferred Tax Assets, Valuation Allowance 123M USD +28.1%
Deferred Tax Assets, Gross 126M USD +28.6%
Operating Lease, Liability 50M USD
Depreciation 6.9M USD +26.7%
Payments to Acquire Property, Plant, and Equipment 533K USD -85.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -234M USD -56.4%
Lessee, Operating Lease, Liability, to be Paid 85.8M USD
Operating Lease, Liability, Current 4.23M USD -32.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 6.62M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 6.85M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 35.8M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 6.48M USD
Deferred Tax Assets, Operating Loss Carryforwards 105M USD +30.3%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.76M USD
Operating Lease, Payments 1.73M USD +33.1%
Additional Paid in Capital 1.55B USD +52.6%
Depreciation, Depletion and Amortization 1.81M USD -4.9%
Share-based Payment Arrangement, Expense 11.4M USD +10%
Interest Expense 64.6M USD +324%